AKT1 and glioblastoma: TRPML-2-deficient U251 and T98 cells (an in vitro model of glioblastoma) showed a reduction in cell proliferation involving the inhibition of AKT and ERK1/2 signalling [36], suggesting that TRPML-2 acts as a regulator of ERK1/2 and AKT signalling pathways in glioblastoma cell proliferation.